Farber Cancer Institute To Their Contract Research Organization Advisory Board

Farber Cancer Institute To Their Contract Research Organization Advisory Board

the other members of Vial’s Contract Research Organization Scientific Advisory Board, will work hand-in-hand with the Vial team to launch and optimize the new Contract Research Organization.

The primary focus of my career has been to develop new drugs and combinations for urinary bladder cancer as well as prostate and kidney cancer through clinical trials. With new treatments like immunotherapies, antibody drug conjugates and targeted therapies, the field is accelerating towards improved cure rates.

However, the clinical trials industry needs to be accelerating at that same pace, which is why I’m looking forward to working with Vial to ensure that trials are run with the utmost efficiency.

Vial has worked closely with sponsors and investigators to develop a deep understanding of the nuances of clinical trials and the current pain points in running them. The result of that research is a tech-enabled Contract Research Organization offering that’s “Built for Sponsors.

The new Contract Research Organization will leverage Vial’s streamlined trial management system that integrates eSource into a seamless operating system. The Contract Research Organization also offers additional best-in-class services to sponsors including more efficient study startup processes, a centralized pre-screening call center, and an unparalleled approach to patient recruitment.

He also has led translational projects and developed prognostic classifications and endpoints focused on bladder cancer. In addition to his roles at the Dana-Farber Cancer Institute and Harvard Medical School member of the Genitourinary Committee of Southwest Group and the Bladder Cancer Task Force of the National Cancer Institute Genitourinary Steering Committee.

Leave a Reply

Your email address will not be published. Required fields are marked *